Reporter brief
GLP-1 agonists associated with lower all-cause mortality in adults with obesity and elevated CRP (matched cohort study)
What happened
This matched cohort study compared 50,009 adults with obesity and C-reactive protein levels of 3-10 mg/L who received GLP-1 receptor agonists to a similar-sized group receiving metformin, orlistat, or phentermine. Over a median follow-up of up to 3,650 days, GLP-1 exposure was associated with a 39% lower hazard of the composite outcome of all-cause mortality, myocardial infarction, and ischemic stroke, with the strongest effect on all-cause mortality (39% lower hazard). Ischemic stroke, arrhythmias, and heart failure with reduced ejection fraction showed modest reductions, while myocardial infarction and heart failure with preserved ejection fraction did not differ significantly.
Why it matters
Assessment pending; this report does not establish a change in evidence.
What it does NOT prove
- Limitations have not been recorded; consult the primary source.
Study design and sample
Cohort; Human.
Adults with body mass index ≥30 kg/m² and C-reactive protein (CRP) levels of 3-10 mg/L
- Design
- Cohort
- Sample
- 100,018
- Journal
- The American journal of cardiology
- Published
- Sep 21, 2026
Effect size
Primary composite outcome: HR 0.799 (95% CI 0.772-0.825); All-cause mortality: HR 0.608 (95% CI 0.578-0.640)
Caveats
- Assessment: Superseded.
- Only the source material recorded on this evidence page was assessed.
Conflicts and funding
Not recorded.
Previous evidence
See the GLP-1 agonists timeline and recorded assessment for prior evidence.
Primary source
Cancel Death charts and briefs may be reproduced editorially with attribution to CancelDeath.com. This brief is generated from the primary recorded source facts and assessment. Its review status is shown below; verify quotations against the paper before publication.